Analyst consensus rating
enGene Therapeutics Analyst Rating: Buy
Direct answer
enGene Therapeutics's consensus rating is Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $3.29.
Forecast evidence checked November 9, 2026.
Get free enGene Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.78
- Average price target
- $3.29
- High price target
- $5.00
- Low price target
- $2.00
- Low target gap
- +12.7%
- Target upside
- +85.1%
- High target gap
- +181.7%
- Target range width
- 169%
- Consensus rating
- Buy
- Analysts
- 7
- Evidence date
- November 9, 2026
- Valid through
- November 16, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for enGene Therapeutics?
enGene Therapeutics has a verified Buy consensus. The same dataset has an average price target of $3.29.
How far are enGene Therapeutics's low and high targets from the recorded price?
The low target implies +12.7%, while the high target implies +181.7%.
How many analysts are included in enGene Therapeutics's consensus?
The verified consensus includes 7 analysts.
How is enGene Therapeutics's target upside or downside calculated?
The average target of $3.29 is divided by the recorded price of $1.78, then one is subtracted to produce +85.1%. This does not guarantee a future return.
When was enGene Therapeutics's analyst forecast verified?
The data was verified on 2026-11-09. The dataset is valid through 2026-11-16.